|
YO-001A, a new antifungal agent produced by Streptomyces sp. YO15-A001 |
YO-001A |
In vitro |
6 Oct 2019 |
|
Ibrexafungerp Overview |
Ibrexafungerp (SCY-078, MK-3118) |
|
3 Jul 2019 |
|
Study to Evaluate the Safety and Efficacy of the Combination Therapy of Ibrexafungerp (SCY-078) With Voriconazole in Patients With Invasive Pulmonary Aspergillosis (SCYNERGIA) |
Ibrexafungerp (SCY-078, MK-3118) |
Phase 2 |
22 Jan 2019 |
|
Open-Label Study to Evaluate Efficacy and Safety of SCY-078 in Patients With Refractory or Intolerant Fungal Diseases (FURI) |
Ibrexafungerp (SCY-078, MK-3118) |
Phase 3 |
1 Apr 2017 |
|
In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies. |
F901318 (olorofim) |
|
25 Mar 2019 |
|
Activity of Ceragenin CSA-131 against Candida Auris |
Ceragenin CSA-131 |
|
9 Apr 2018 |
|
Preclinical Evaluation of the Stability, Safety and Efficacy of CD101, a Novel Echinocandin |
CD101 |
In vivo |
1 Nov 2017 |
|
New and emerging treatments for fungal infections. |
Albaconazole |
|
20 Oct 2017 |
|
Biafungin (CD101), a Novel Echinocandin, Displays a Long Half-life in the Chimpanzee, Suggesting a Once-Weekly IV Dosing Option |
Biafungin (CD101) |
|
20 Oct 2017 |
|
Biafungin (CD101), a Novel Echinocandin, Displays an Uncommonly Long Half-life in Multiple Species |
Biafungin (CD101) |
|
20 Oct 2017 |
